Society of Hematologic Oncology Annual Meeting

Jorge Cortes, MD, received Society of Hematologic Oncology’s Michael J. Keating Outstanding Achievement Award.

Hagop Kantarjian, MD, received Society of Hematologic Oncology’s Emil J Freireich Distinguished Pioneer Award.

The addition of metformin to standard chemotherapy improved outcomes for patients with diffuse large B-cell lymphoma, according to findings presented at Society of Hematologic Oncology Annual Meeting.

An infusion of lisocabtagene maraleucel induced deep and durable responses among most adults with relapsed or refractory follicular lymphoma, according to results of the phase 2 TRANSCEND FL trial.

Patients with multiple myeloma who exhibited sustained minimal residual disease negativity after treatment with ciltacabtagene autoleucel achieved longer PFS and duration of response, according to study results.

Study results presented at Society of Hematologic Oncology Annual Meeting highlight the potential effect that socio-racial characteristics may have on outcomes of patients with primary myelofibrosis.

Early response to ponatinib appeared predictive of survival among certain patients with chronic myeloid leukemia, according to findings presented at Society of Hematologic Oncology Annual Meeting.

Intensive consolidation chemotherapy prior to allogeneic hematopoietic stem cell transplant provided no greater benefit than nonintensive consolidation for older adults with acute myeloid leukemia, according to study results.

Several factors contributed to inequities of outcomes among people with hematologic malignancies in the United States, according to findings presented at Society of Hematologic Oncology Annual Meeting.

Ponatinib improved outcomes compared with imatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, according to study results presented at Society of Hematologic Oncology Annual Meeting.